Pharmacogenetics of Apolipoprotein E Gene During Lipid-Lowering Therapy: Lipid Levels and Prevention of Coronary Heart Disease
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A non-optimal plasma concentration of lipids is among the major modifiable risk factors of atherosclerosis. Therefore, the prevention of cardiovascular disease by means of lipid-lowering therapy with statins and other agents is of great importance for patient groups where a lifestyle change, for example, diet modification, does not lead to adequately reduced lipid levels. The response of low-density-lipoprotein cholesterol (LDL-C) levels to statin therapy is highly variable. This is partly attributed to hereditary variation in genes involved in pharmacokinetics, pharmacodynamics and lipid metabolism. The pharmacogenetics of lipid-lowering therapy have been investigated for more than 40 different genes. The gene for apolipoprotein E (APOE) has been the most frequently studied, particularly regarding the epsilon2/epsilon3/epsilon4 polymorphism. Those with the epsilon4 allele seem to have the poorest and those with the epsilon2 allele the strongest response to statins with regards to LDL-C levels. In addition, the epsilon2 carriers may reach the LDL-C treatment goals more frequently than epsilon4 carriers. Few studies have investigated the interaction of the APOE epsilon2/epsilon3/epsilon4 polymorphism and lipid-lowering therapy in relation to the course of coronary heart disease; the results are contradictory and so far inconclusive. This review summarizes the pharmacogenetic findings related to the influence of APOE gene variation on lipid responses and the prevention of coronary heart disease during lipid-lowering therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Association of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794
Human apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man
UTERMANN, G., HEES, M., & STEINMETZ, A. (1977) · Nature · doi:10.1038/269604a0 · Cited by 666
Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease
Song, Y., Stampfer, M. J., & Liu, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-2-200407200-00013 · Cited by 528
Apolipoprotein-mediated pathways of lipid antigen presentation
Elzen, P. V. D., Garg, S., León, L., Brigl, M., Leadbetter, E. A., Gumperz, J. E., Dascher, C. C., Cheng, T.-Y., Sacks, F. M., Illarionov, P. A., et al. (2005) · Nature · doi:10.1038/nature04001 · Cited by 380
Abnormal in vivo metabolism of apolipoprotein E4 in humans.
Gregg, R. E., Zech, L. A., Schaefer, E. J., Stark, D., Wilson, D., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112645 · Cited by 345
Research works printed but not linked: 73
- 10.1021/bi00727a022 · DOI · Paper page
- Boerwinkle E , UtermannG: Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism.Am. J. Hum. Genet.42, 104–112 (1988).
- 10.1172/JCI113107 · DOI · Paper page
- 10.1161/01.ATV.18.9.1424 · DOI
- Zannis VI , JustPW, BreslowJL: Human apolipoprotein E isoprotein subclasses are genetically determined.Am. J. Hum. Genet.33, 11–24 (1981).
- 10.1016/S0021-9150(99)00501-8 · DOI
- 10.1353/hub.2008.0003 · doi:10.1353/hub.2008.0003
- 10.1016/S0022-2275(20)43170-0 · DOI · Paper page
- 10.1093/hmg/7.12.1887 · DOI · Paper page
- 10.1097/00001756-199903170-00038 · DOI · Paper page
- 10.1056/NEJM199511163332001 · DOI · Paper page
- 10.1016/S0140-6736(94)91755-8 · DOI · Paper page
- 10.1056/NEJM199610033351401 · DOI · Paper page
- 10.1016/S0140-6736(05)67394-1 · DOI · Paper page
- 10.1586/14779072.6.4.447 · DOI
- 10.1016/S0021-9150(00)00383-X · DOI
- 10.3109/07853899109147932 · DOI
- 10.1515/CCLM.2007.116 · DOI · Paper page
- 10.1016/S0022-2275(20)38503-5 · DOI · Paper page
- 10.1016/0021-9150(86)90080-8 · DOI
- Werb Z , ChinJR, TakemuraR et al.: The cell and molecular biology of apolipoprotein E synthesis by macrophages. Ciba Found. Symp.118, 155–171 (1986).
- 10.1016/S0022-2275(20)40076-8 · DOI · Paper page
- 10.1172/JCI119887 · DOI · Paper page
- 10.1515/CCLM.2000.068 · doi:10.1515/cclm.2000.068
- 10.1111/j.1365-2265.2006.02455.x · DOI
- 10.1515/CCLM.2008.033 · DOI
- 10.1093/hmg/9.1.57 · DOI · Paper page
- 10.1038/sj.ejhg.5200983 · DOI
- 10.1016/j.clinbiochem.2006.02.002 · DOI
- 10.1016/j.clinbiochem.2007.06.010 · DOI
- 10.1038/ejhg.2008.27 · DOI
- 10.1161/01.CIR.100.6.608 · DOI · Paper page
- 10.1056/NEJM199404143301503 · DOI · Paper page
- 10.1161/01.ATV.21.5.832 · DOI
- 10.1111/j.1365-2796.1991.tb00464.x · DOI
- 10.1016/0026-0495(93)90066-W · DOI
- 10.1016/S0735-1097(00)00918-9 · DOI · Paper page
- 10.1007/s10038-006-0025-1 · DOI
- 10.1177/00912700122012643 · DOI
- 10.1016/j.amjcard.2003.06.008 · DOI
- 10.1038/sj.tpj.6500328 · DOI · Paper page
- 10.1016/0021-9150(94)05439-P · DOI · Paper page
- 10.1016/S0021-9150(96)06031-5 · DOI
- 10.2143/AC.61.3.2014836 · DOI
- 10.1097/FPC.0b013e3282f60aad · DOI
- 10.1111/j.1463-1326.2006.00577.x · DOI
- 10.1016/S0021-9150(01)00410-5 · DOI · Paper page
- 10.1097/00008571-200304000-00006 · DOI
- 10.1111/j.1365-2796.1993.tb00670.x · DOI · Paper page
- 10.1016/0026-0495(90)90068-N · DOI
- 10.1177/1074248406293732 · DOI
- 10.1016/0021-9150(90)90134-5 · DOI
- 10.1016/0168-8227(93)90018-Z · DOI
- 10.1046/j.1365-2796.2002.00991.x · DOI
- 10.1046/j.1365-2362.2002.00996.x · DOI
- 10.1185/030079907X199817 · DOI
- 10.1161/01.CIR.101.12.1366 · DOI · Paper page
- 10.1097/00008571-200211000-00009 · DOI
- 10.1093/eurheartj/ehm196 · DOI
- 10.1080/00365510701297472 · DOI
- 10.1016/j.amjcard.2005.08.011 · DOI
- 10.1097/MOL.0b013e3280555083 · DOI
- 10.1097/MOL.0b013e328235a5a2 · DOI
- 10.1038/sj.tpj.6500384 · DOI · Paper page
- 10.1097/MOL.0b013e32825a6773 · DOI · Paper page
- 10.1371/journal.pone.0000097 · DOI · Paper page
- 10.1016/S0026-0495(98)90240-2 · DOI
- 10.1016/S0021-9150(01)00584-6 · DOI
- Ye P , ShangY, DingX: The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia.Chin. Med. Sci. J.18, 9–13 (2003).
- 10.2174/1567205043480546 · doi:10.2174/1567205043480546
- 10.1016/j.cccn.2005.06.005 · DOI
- 10.1097/01213011-200504000-00005 · DOI
- 10.1016/j.phrs.2006.12.009 · DOI
Cited by
APOE alleles and diet in brain aging and Alzheimer's disease
Yassine, H. N., & Finch, C. E. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00150 · Cited by 145
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Darreh-Shori, T., Forsberg, A., Modiri, N., Andreasen, N., Blennow, K., Kamil, C., Ahmed, H., Almkvist, O., Långström, B., & Nordberg, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.028 · Cited by 64
Vijayaraghavan, S., Maetzler, W., Reimold, M., Lithner, C. U., Liepelt‐Scarfone, I., Berg, D., & Darreh‐Shori, T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.010 · Cited by 24
Metadata
- Authors
- Nieminen, T., Kähönen, M., Viiri, L. E., Grönroos, P., & Lehtimäki, T.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 1475-1486
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2104465297
- Cited by
- 77
- References
- 19
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Emil Aaltonen Foundation
- Finnish Foundation of Cardiovascular Research
- Medical Research Fund of Tampere University Hospital
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics of Apolipoprotein E Gene During Lipid-Lowering Therapy: Lipid Levels and Prevention of Coronary Heart Disease. https://app.cochat.ai/papers/10.2217/14622416.9.10.1475
- The paper
- Nieminen, T., Kähönen, M., Viiri, L. E., Grönroos, P., & Lehtimäki, T. (2008). Pharmacogenetics of Apolipoprotein E Gene During Lipid-Lowering Therapy: Lipid Levels and Prevention of Coronary Heart Disease. Pharmacogenomics. https://doi.org/10.2217/14622416.9.10.1475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.